Status:
COMPLETED
Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)
Lead Sponsor:
Osaka University
Conditions:
Pulmonary Tuberculosis
Eligibility:
All Genders
20-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to elucidate whether the individualized medicine based on NAT2 gene polymorphism could improve the safety, efficacy and economical benefits of multi-drug therapy for the p...
Eligibility Criteria
Inclusion
- Newly diagnosed pulmonary tuberculosis patients
- Informed consent including pharmacogenomic analysis
Exclusion
- Abnormal liver and kidney function test before treatment
- Long-term use of steroids and/or immunodepressants
- Inadequate clinical conditions
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT00298870
Start Date
June 1 2005
Last Update
October 18 2012
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Osaka Prefectural Medical Center for Respiratory and Allergic Diseases
Habikino, Osaka, Japan, 583-8588
2
Osaka Hospital, Anti-Tuberculosis Association, Osaka Branch
Neyagawa, Osaka, Japan, 572-0801
3
National Hospital Organization Kinki-chuo Chest Medical Center
Sakai, Osaka, Japan, 591-8555
4
National Hospital Organization Toneyama
Toyonaka, Osaka, Japan, 560-8552